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Summary box
 Ź The evidence surrounding the cost-effectiveness of 
performance-based inancing (PBF) is weak, and it is 
not clear how PBF compares with alternative inter-
ventions in terms of its value for money.
 Ź It is important to ill this evidence gap as countries 
transition from aid and face increasing budget con-
straints and competing priorities for the use of their 
domestic resources.
 Ź In conducting cost-effectiveness analyses of PBF, 
researchers should be mindful of the identiication, 
measurement and valuation of costs and effects, 
provide justiication for the scope of their studies, 
and specify appropriate comparators and decision 
rules.
 Ź We also recommend the use of a reference case 
to lay out the principles, preferred methodolog-
ical choices and reporting standards, as well as a 
checklist.
INTRODUCTION
In the last two decades, performance-based 
financing (PBF) has gained worldwide prom-
inence. As of September 2016, the Health 
Results Innovation Trust Fund (HRITF) at 
the World Bank supported 29 low-income and 
middle-income countries in the introduction, 
implementation and evaluation of 35 PBF 
programmes, with expenditure near $2.5 
billion. Although PBF is perceived as a tool to 
achieve the Sustainable Development Goals, 
several global health experts have pointed to 
its mixed evidence base.1 In recent years, PBF 
has become one of the most divisive topics in 
the global health community, as illustrated by 
the lively discussions following the publica-
tion of Paul et al’s piece.2
Policy-makers need to assess whether PBF is 
an appropriate policy choice for their coun-
tries, given the substantial budget constraints 
they face and that are likely to worsen with 
transition from aid. In practice, whether 
the investments required to implement 
PBF are ‘worthwhile’ is a question that can 
be answered by a cost-effectiveness analysis 
(CEA). However, a recent review found no 
studies making clear connections between the 
costs and effects of PBF.3 Our search yielded 
three CEAs of PBF; only one was peer-re-
viewed.4–6 This commentary reviews those 
studies and discusses potential methodolog-
ical pitfalls. We also seek to offer construc-
tive ways to move forward with undertaking 
robust CEA.
HOW CEA CAN BE APPLIED TO PBF
CEA synthesises the evidence on the costs 
and effectiveness of an intervention. The 
outcome of a CEA is usually the incremental 
cost-effectiveness ratio (ICER), which is the 
difference in costs between two interven-
tions divided by the difference in their health 
outcomes. Health effects are often meas-
ured as averted disability-adjusted life years 
(DALYs) or gained quality-adjusted life years 
(QALYs). The main objective of CEAs is to 
rank interventions according to their costs 
and effectiveness, allowing policy-makers to 
select interventions that produce the greatest 
health at the lowest cost.7 In other words, CEA 
will show how PBF compares with other inter-
ventions, and whether investments to support 
PBF could produce better health outcomes 
than alternative spending scenarios.
Although the key ingredients of CEAs—
information on cost and impact—are in 
principle available for a number of PBF 
programmes, carrying out a CEA for this 
kind of complex intervention is challenging. 
In particular, assessing the effectiveness of 
PBF through direct measurement or model-
ling can be difficult. PBF is a complex inter-
vention that is likely to influence health 
outcomes through multiple and intricate 
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channels, including spillovers from increased provider 
autonomy, improved health information systems, moni-
toring of quality of care and public finance manage-
ment.8 There is currently little guidance on how to gauge 
the effectiveness for complex interventions like PBF, 
and no clear framework for extrapolating from effects 
on, for example, service utilisation and quality to health 
outcomes. As a result, studies use different modelling 
approaches that are not validated and do not align with 
the traditional CEA literature. This, in turn, makes it 
difficult to compare CEAs of PBF with those of alterna-
tive policy choices or draw meaningful conclusions on 
the value of PBF. For example, the CEA of the Zambia 
PBF programme used a combination of estimates from 
the Lives Saved Tool and Delphi panels to extrapolate 
from changes in access to essential services and quality 
indicators to health outcomes.4 The effectiveness of 
PBF is expressed in terms of ‘Quality adjusted QALYs’, 
a novel measure that cannot be compared with existing 
literature.
TOWARDS INFORMATIVE CEAS OF PBF
We recommend the following steps towards generating 
CEA studies for PBF: performing systematic and trans-
parent identification, measurement, and valuation of 
appropriate costs and effects, providing justification for 
the scope of the CEA, and deciding on a clear compar-
ator against which PBF will be assessed and applying a 
relevant decision rule criterion. Although inherent 
trade-offs will remain, these steps are feasible and could 
substantially advance the base of policy-relevant evidence 
on PBF.
First, the costing perspective needs to be aligned 
with the objectives of the CEA (eg, to inform country 
or donor decisions) and be consistent with the costing 
methods. Studies using a health systems’ perspective 
should include all relevant costs to the health system. 
Typically, this requires information on activities that are 
often not the evaluators’ focus, such as measuring time 
usage patterns of providers. For instance, the Zambian 
PBF CEA did not account for this cost category,4 but it 
appears to be important elsewhere (eg, in the Tanzanian 
PBF programme, 17% of provider time was associated 
with entering and verifying performance data5). Failure 
to include these costs will impact the cost estimates of 
PBF and make it hard to compare results across studies as 
standard CEA practice would include such costs. Having 
clearly laid out methods for costing is essential to ensure 
that all costs are accounted for and that studies use 
comparable methods. The Reference Case for Estimating 
the Costs of Global Health Services and Interventions 
provides an excellent resource on this subject.9
A second step is to define what is meant by effective-
ness of PBF programmes, and how to measure and/or 
model it. Typically, decision analytic modelling is used 
in CEAs to extrapolate from intermediary or short-term 
outputs to final and longer term outcomes (eg, health 
outcomes). PBF is unique as it has multiple objectives 
and impacts health through different direct or indi-
rect channels. However, measuring changes in health 
outcomes or quality of life (eg, through household 
surveys) is commonly used to perform such modelling. 
In a CEA study of the Plan Nacer (a PBF programme) 
in Argentina, changes in birth outcomes and neonatal 
mortality were used in tandem to estimate DALYs 
averted.6 However, there is no existing clear framework 
for measuring or modelling the effects of complex inter-
ventions like PBF.
Special attention should also be given to the scope 
of the CEA. In some countries, PBF programmes are 
large and affect several disease areas at once, possibly 
over varying lengths of time. Evaluating the entirety of 
a PBF programme might not be possible. Moreover, PBF 
seems to be more effective at improving some aspects of 
care than others.1 As a result, focusing on a segment of 
the programme (eg, child health) and a specific expo-
sure period might be preferable. Should the researchers 
decide to only focus on specific aspects, a robust justifica-
tion for selecting the areas of care is needed. The decision 
rule should be decided from the onset,10 and researchers 
should not select areas of care where measured effective-
ness is the largest and discard evidence from areas that 
show no impact. The decision rule in Zambia was not 
clear.4 Moreover, rigorous methods for attributing costs 
to the relevant segment should be applied and clearly 
reported. This can be challenging, especially when it 
comes to fixed costs. Time and motion surveys, facility 
surveys, and provider surveys can help with identifying 
costs accruing to certain services.
When possible, expected costs and effects should 
be considered for all relevant alternatives to PBF. For 
instance, some HRITF studies sought to compare PBF 
with unconditional cash disbursements. Another option 
could be to compare PBF with an approach of perfor-
mance monitoring without incentive payments. When 
doing so, a full incremental analysis should be conducted. 
In other words, the estimated costs and health generated 
should be reported for each intervention arm, along with 
the corresponding ICERs. That way, the relevant cost-ef-
fective option can be identified. None of the reviewed 
studies presented this information clearly, which limited 
our ability, as readers, to clearly interpret the results.
Finally, decision rules (ie, how we decide whether an 
intervention is cost-effective or not) should be laid out 
clearly from the onset. The PBF programmes in Argen-
tina and Zambia were judged to be cost-effective because 
the ICER was lower than a predefined threshold based 
on gross domestic product (GDP).4 6 While the use of a 
threshold is not uncommon, several experts (including 
at the WHO, where the practice originated) have empha-
sised that GDP-based thresholds are set too high and will 
lead to the inclusion of unaffordable interventions. Deci-
sion thresholds could be set lower11 (although this pres-
ents its own caveats7) or could be derived from available 
budgets.
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CONCLUSION
It is important to evaluate how PBF compares with other 
policies in terms of costs in addition to effectiveness, as 
country budgets are expected to take over the funding of 
PBF programmes in the long term.12
No perfect design for CEA of PBF exists, and 
researchers will be faced with important trade-offs. Some 
of those trade-offs are discussed in Shepard et al,10 and 
this commentary raises additional points. Planning for 
a CEA should be incorporated from the outset, to help 
define the decision problem, identify data collection 
needs and avoid retrospectively making up for data gaps. 
Methodological standards used in the general CEA liter-
ature should be followed and methods reported explic-
itly, allowing readers to judge the applicability of the PBF 
programme to their own setting and enabling compari-
sons and replication. Preregistration of the analysis plans, 
as done in clinical trials, could be used to get external 
comments and further strengthen the legitimacy and 
credibility of studies. We also strongly encourage the 
use of a reference case that clearly lays out principles, 
preferred methodological choices and reporting stan-
dards, with specific methodological discussions and spec-
ifications to accommodate the peculiarities of PBF. A 
starting point could be the Reference Case for Economic 
Evaluation developed by the International Decision 
Support Initiative13; the development of a checklist can 
also be envisaged.
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